BCL2 and neuroblastoma: A direct comparison of the efficacy of the different compounds as calculated from viability data revealed that three out of 14 cell lines were sensitive to ABT-199 at concentrations below 3 μM (SJNB-12, CHLA-15 and Lan-5) and, similarly, three out of 14 responded to S63845 (SJNB-12, Kelly and CHP-212) and three out of 14 displayed sensitivity to A1331852 (IMR-32, Lan-5 and CHLA-15), highlighting that besides BCL-2, also MCL-1 and BCL-XL may be promising therapeutic targets in neuroblastoma.